Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations ...

U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent ...

U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent ...

Upcoming earnings releases in Asia, as well as the rest of the world, also added to the wait-and-see mood. On Wall Street, the S&P 500 slipped 0.3% to 5,813.67 after drifting between small gains and ...

Q3 sales in weight loss drugs Mounjaro and Zepbound were more than 20% lower than consensus analyst forecasts, spooking investors.

Over the last month, Dell and Super Micro have been sparring in the headlines with new product releases. Just two weeks ago, ...

The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its ...

U.S. stock indexes gave up an early gain and ended slightly lower following a mixed set of profit reports from giants like ...

Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...